Conmed (CNMD) Tops Q3 EPS by 7c, offers guidace

Conmed (NYSE: CNMD) reported Q3 EPS of $0.90, $0.07 better than the analyst estimate of $0.83. Revenue for the quarter came in at $304.6 million versus the consensus estimate of $300.91 million.

2023 Outlook

Based on the third quarter results, the Company now expects full-year revenue between $1.240 billion and $1.260 billion, compared to its prior guidance of between $1.230 billion and $1.260 billion.

The Company now expects full-year 2023 adjusted diluted net earnings per share(2) in the range of $3.45 to $3.55, compared to its prior range of $3.40 to $3.55 v/s the consensus of $3.48

The expected impact of foreign currency exchange rates remains consistent with the range provided in our original guidance for 2023.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• BMO Capital Reiterates Market Perform Rating on Axalta Coating Systems (AXTA)